Comparison of dual-color dual-hapten brightfield in situ hybridization (DDISH) and fluorescence in situ hybridization in breast cancer HER2 assessment

Kósa, C; Kardos, Lászĺo; Kovács, Judit Sándorné; Szöllősi, Zoltán

doi:10.1016/j.prp.2013.01.006

Cited by 15 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Ki67 LI was assessed by estimation using 10% steps except for the area between 10% and 20% for which 5% steps were used. 38 If a distinction between 10% steps was not possible, a range for Ki67 LI (e.g., 20-30%) was included in the pathological report. Immunohistochemistry and in situ hybridization were performed on an automated stainer (BenchMark Ultra TM , Roche-Ventana Ò ).…”

Section: Pretherapeutic Proceduresmentioning

confidence: 99%

Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy

et al. 2019

View full text Add to dashboard Cite

Background. Assessing the residual cancer burden (RCB) predictive performance, the potential subgroup effects, and time-dependent impact on breast cancer patients who underwent neoadjuvant therapy in a developer's independent cohort is essential for its usage in clinical routine. Methods. Between 2011 and 2016, the RCB scores of 184 female breast cancer patients were prospectively collected, and subsequent clinicopathological and follow-up data were obtained retrospectively. Recurrence-free survival (RFS), overall survival (OS), as well as subgroup analysis, and time-dependent variables were calculated with multivariate, complex, or linear statistical models. Results. A total of 184 patients (HER2 33%, TNBC 27%), with a mean follow-up time of 4 years, treated with neoadjuvant systemic therapy (92% anthracycline-taxane based) were analyzed revealing 43 events (38 recurrences, 28 deaths). High RCB scores were associated with recurrence (median index: 2.34 vs. 1.39 points, rank-sum p \ 0.0001), decreased RFS (hazard ratio [HR] = 1.80, 95% confidence interval [CI] 1.44-2.24, p \ 0.0001) and reduced OS (HR 1.96, 95% CI 1.49-2.59, p \ 0.0001). The RCB score showed proportionality of hazards (interaction HR with linear follow-up time = 1.00, p = 0.896) and good discriminating power (Harrell's c index 0.7). Conclusions. Our results confirm the RCB score as externally valid prognostic marker and being independent of molecular subtype for RFS and OS in a clinical setting.

show abstract

Section: Pretherapeutic Proceduresmentioning

confidence: 99%

Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The relative standard deviation was found to be 2.4%, showing a good reproducibility and acceptable precision. 15 …”

Section: Repeatabilitymentioning

confidence: 99%

“…Transducer systems for biosensors are mainly optical [14][15][16], piezoelectric or electrochemical [17][18][19]. Among these, the electrochemical immunosensors have been well established as valid alternatives to classical analysis methods for detection of cancer markers, by offering the advantages of being easy to use, rapid, robust and often inexpensive and capable of multi-analyte testing [19].…”

Section: Introductionmentioning

confidence: 99%

A novel antibody–antigen based impedimetric immunosensor for low level detection of HER2 in serum samples of breast cancer patients via modification of a gold nanoparticles decorated multiwall carbon nanotube-ionic liquid electrode

Arkan

Saber

Karimi

et al. 2015

Analytica Chimica Acta

147

View full text Add to dashboard Cite

“…Immunohistochemistry (IHC) and in situ hybridization (ISH) are considered the gold standard tests for HER2 assessment in breast carcinoma (Wolff et al, ). IHC evaluates HER2 protein expression and ISH detects HER2 copy number using fluorescent (FISH), chromogenic (CISH), or silver (SISH) detection systems or their combination by bright‐field double ISH (BDISH) or dual‐color dual‐hapten ISH (DDISH) (Kurosumi, ; Kosa et al, ). HER2 gene status may be evaluated by single‐probe but more often is evaluated by dual‐probe ISH together with a probe detecting the centromeric region of chromosome 17 (CEP17).…”

Section: Introductionmentioning

confidence: 99%

Frequency of chromosome 17 polysomy in relation to CEP17 copy number in a large breast cancer cohort

Koudeláková

Trojanec

Vrbková

et al. 2016

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

Eligibility to anti-HER2 therapy for breast tumors strictly depends on demonstrating HER2 overexpression (by immunohistochemistry) or HER2 gene amplification by in situ hybridization (ISH), usually defined by the ratio of HER2 gene to chromosome 17 centromere (CEP17) copies. However, the CEP17 copy number increase (CNI) has been proven responsible for misleading HER2 FISH results and recent small cohort studies suggest that chromosome 17 polysomy is actually very rare. Here we investigated by FISH the frequency of true chromosome 17 polysomy in a consecutive cohort of 5,477 invasive breast cancer patients. We evaluated and selected the LSI 17p11.2 probe for chromosome 17 enumeration on a training cohort of 67 breast cancer samples (CEP17 ≥ 2.5). LSI 17p11.2 was used in the 297/5,477 patients from the validation cohort displaying CEP17 CNI (CEP17 ≥ 3.0). Using HER2/17p11.2 scoring criteria, 37.3%/1.5% patients initially classified as equivocal/non-amplified were reclassified as amplified. For a more accurate assessment of chromosome 17 and ploidy in the samples, we tested six markers located on chromosome 17 and centromeric regions of chromosome 8 (CEP8) and 11 (CEP11) in 67 patients with CEP17 and LSI 17p11.2 CNI. True polysomy (hyperdiploidy) according to these markers was found in 0.48% of cases (24/5,020). CEP8 and CEP11 CNI (≥3.0) was more frequent in the hyperdiploid than CEP17 non-polysomic group (55.6% vs. 6.1% and 25% vs. 2.3%, respectively). Our results suggest that chromosome 17 polysomy is a rare event found in <1% breast cancer cases and that polysomy of other chromosomes frequently occurs with chromosome 17 polysomy.

show abstract

Comparison of dual-color dual-hapten brightfield in situ hybridization (DDISH) and fluorescence in situ hybridization in breast cancer HER2 assessment

Cited by 15 publications

References 15 publications

Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy

Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy

A novel antibody–antigen based impedimetric immunosensor for low level detection of HER2 in serum samples of breast cancer patients via modification of a gold nanoparticles decorated multiwall carbon nanotube-ionic liquid electrode

Frequency of chromosome 17 polysomy in relation to CEP17 copy number in a large breast cancer cohort

Contact Info

Product

Resources

About